Press coverage about Seattle Genetics (NASDAQ:SGEN) has been trending positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Seattle Genetics earned a news impact score of 0.26 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.6673686321354 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- Seattle Genetics Announces Expiration of Hart-Scott-Rodino Waiting Period (finance.yahoo.com)
- BRIEF-Seattle Genetics Announces Expiration Of Hart-Scott-Rodino Waiting Period (feeds.reuters.com)
- Reviewing Seattle Genetics (SGEN) and Cellectis (CLLS) (americanbankingnews.com)
- PharmaMar octroie des charges utiles d’origine marine entièrement synthétiques sous licence à Seattle Genetics pour les utiliser dans des conjugués de médicaments (prnewswire.com)
- PharmaMar concede in licenza a Seattle Genetics composti sintetici di origine marina per l’utilizzo in coniugati farmaceutici (prnewswire.com)
A number of analysts have weighed in on SGEN shares. HC Wainwright restated a “buy” rating and set a $75.00 price objective on shares of Seattle Genetics in a research note on Friday, October 27th. Jefferies Group reiterated a “buy” rating and issued a $53.00 price target on shares of Seattle Genetics in a research note on Thursday, October 26th. Guggenheim reiterated a “buy” rating and issued a $72.00 price target on shares of Seattle Genetics in a research note on Monday, October 23rd. Zacks Investment Research upgraded shares of Seattle Genetics from a “hold” rating to a “buy” rating and set a $70.00 price target for the company in a research note on Tuesday, October 31st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $74.00 price target (up from $72.00) on shares of Seattle Genetics in a research note on Wednesday, February 7th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $64.25.
Seattle Genetics (NASDAQ:SGEN) last posted its quarterly earnings data on Tuesday, February 6th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.02. The company had revenue of $129.61 million for the quarter, compared to the consensus estimate of $123.99 million. Seattle Genetics had a negative net margin of 26.03% and a negative return on equity of 33.36%. The firm’s revenue was up 23.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.39) earnings per share. analysts forecast that Seattle Genetics will post -1.59 EPS for the current fiscal year.
In related news, insider Vaughn B. Himes sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $59.97, for a total value of $599,700.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Eric Dobmeier sold 3,729 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $58.75, for a total transaction of $219,078.75. The disclosure for this sale can be found here. In the last three months, insiders sold 70,225 shares of company stock worth $3,772,766. 34.70% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Seattle Genetics (SGEN) Earning Favorable News Coverage, Report Finds” was posted by Week Herald and is owned by of Week Herald. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://weekherald.com/2018/02/17/seattle-genetics-sgen-earning-favorable-news-coverage-report-finds.html.
About Seattle Genetics
Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).
Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.